Navigation Links
NIH Funds Synedgen to Develop a New Drug to Improve Airway Clearance

Claremont, CA (PRWEB) September 27, 2013

Synedgen announces the award of a National Heart Lung and Blood Institute (NHLBI) Small Business Innovation Research grant from the NIH to explore the mechanisms of a natural modified biopolymer to both reduce the viscosity of mucus and the cohesion of biofilms, potentially leading to a pulmonary treatment for patients with cystic fibrosis (CF) to enhance airway clearance and augment the activity of standard therapeutic antibiotics. In preliminary studies, this new approach to controlling molecular interactions in thick sputum and biofilms has shown significant reductions in viscosity and cohesion.

Due to a genetic defect, CF patients have thicker mucus in their lungs and respiratory tract that is very difficult to clear. The resulting accumulation of mucus allows for colonization by biofilm-producing bacteria. The combination of thick mucus and invasive bacterial biofilms can dramatically reduce lung function of CF patients. Because the biofilms provide a sheltered environment to protect bacteria from antibiotic treatments, CF patients typically suffer from persistent and recurrent lung infections.

In partnership with Dr. Steven Rowe, Associate Professor School of Medicine, University of Alabama Birmingham (UAB), and Director of the CFF Therapeutics Development Network’s Center for CFTR Detection, researchers will be assessing a new drug’s role in reducing the viscosity of patient derived sputum. Using human bronchial cell lines that have the CF defect, they will study the drug’s effect on the relationship of sputum viscosity and mucociliary clearance by assessing activity on monolayers of ciliated cells. Since the drug has already been shown to disrupt biofilms, studies to examine the combined effect of the drug with standard antibiotic treatments will explore the effects of this new drug in enhancing the antibiotic therapies used in CF patients.

“Our approach is to tackle biofilms and sputum, reducing their cohesion and viscosity to allow the patient to clear them both. Our preliminary data demonstrates that our polymeric drug both reduces the viscosity of CF sputum and improves sputum mobility in vitro, and separately loosens biofilms,” stated Synedgen President Shenda Baker. “We hypothesize the drug will have significant synergistic activity with traditional antibiotics, and are eager to explore the magnitude and duration of these effects in mucus, biofilms, and in combination.”

In other studies of pathogenic infection and mucosal surface damage, this new drug has been shown to reduce inflammation at the surface. Since cystic fibrosis is a disease severely affected by airway inflammation, future studies will also examine the drug’s potential additional role in mitigating pulmonary inflammation.

“The preliminary data are extremely exciting,” stated Dr. Steven Rowe, “and could provide a new avenue to address mucus stasis in CF lung disease, potentially improving lung health.”

Preliminary results from these studies will be presented in October at the 27th Annual North American Cystic Fibrosis Conference. Synedgen hopes its new drug will make the sputum flow more freely, break up pathogenic biofilms and also enhance activity of standard antibiotics, providing a new and highly effective pulmonary treatment to help CF patients breathe more easily and combat lung infections.

Research reported in this press release was supported by the National Heart Lung and Blood Institute of the National Institutes of Health under award number 1R43HL118867. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces. Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. QB3-Industry Biotech Startup Partnership Funds Two Projects
3. German Academic Exchange Service funds international project on spintronics
4. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
5. Express Diagnostics to Raise Funds for American Cancer Society During Blue Earth’s Giant Days Parade
6. Kitware Receives Funds from U.S. Air Force Research Lab to Extend the Bender Toolkit for Anatomical Model Repositioning
7. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
10. Scarred for Life? Synedgen Hopes Not
11. Synedgen's Synoplex® is Headed to the Lewa Wildlife Conservancy in Kenya
Post Your Comments:
(Date:10/9/2015)... Inc., (NASDAQ: PULM ) will be webcasting the Company,s ... th Annual BIO Investor Forum on Tuesday, October 20, ... --> th Annual BIO Investor Forum on Tuesday, ... --> Pulmatrix will be presenting at the ... October 15, 2015 at 8:30 am EDT. Additionally, the Company ...
(Date:10/8/2015)... PALM BEACH, Fla. , Oct. 8, 2015 /PRNewswire/ ... leader in synthetic biology, today announced the appointment of ... Head of Environment Sector, succeeding Nir Nimrodi ... Development.  Mr. Vaillancourt will direct Intrexon,s endeavors to generate ... North America , where he held a ...
(Date:10/8/2015)... WAYNE, Pa. , Oct. 8, 2015  Clarkston ... announced the call for applications for the 2016 Clarkston ... in a life sciences related field of study, a ... the selected Clarkston Scholar will receive exposure to the ... participation in Pennsylvania Bio events over the course of ...
(Date:10/8/2015)... RICHARDSON, Texas , Oct. 8, 2015 The 2015 ... graduate of The University of Texas at Dallas. Aziz ... from UT Dallas in 1977, is one ... detailing how cells continuously monitor and repair damaged DNA on a ... PhD in molecular and cell biology from UT Dallas ...
Breaking Biology Technology:
... drive to make healthcare information technology interoperable across ... and a medical information technology company headquartered here ... is lending its expertise to developing an ... the healthcare industry. Specifically, the expertise of Damien ...
... Sonic Foundry, Inc. has announced that it ... the fourth quarter of 2006, its first cash-positive quarter ... been building toward profitability since moving into the rich-media ... which the company showcased new search technology. , ,The ...
... . - Following weeks of blistering criticism of its electronic ... Foundation Health Plan , Madison's Epic Systems Corp . ... defending its product. , ,Epic Systems, a medical software developer, ... its electronic records system, which Kaiser has re-branded with the ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring ... for 2015. So says a new report on the industry ... management segment dominate the market, followed by continuous glucose monitoring ... reports on the market for these products in its latest ... ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
(Date:9/26/2015)... 2015  Results of a TactioRPM pilot project ... at the Stanford Medicine X Conference. In a ... Connected Health Devices and Pharmacogenomics", Roger Simard ... explain how senior patients equipped with connected health ... via the TactioRPM remote patient monitoring platform were ...
Breaking Biology News(10 mins):
... in traffic may cause a headache, but a delay ... of Missouri researchers have uncovered clues identifying which proteins ... and found that the proteins previously thought to play ... the nervous system develops will give researchers a better ...
... A team of Vanderbilt University Medical Center investigators has ... a new class of drugs for treating cancer., The ... phospholipase D (PLD), an enzyme that has been implicated ... colorectal., The new inhibitors, reported in the February issue ...
... gardening can offer enough moderate physical activity to keep older ... February in the journal HortScience , the researchers discovered ... older hands strong and nimble. "One of the things ... better hand strength and pinch force, which is a big ...
Cached Biology News:
... is an anodized aluminum, solvent-resistant block specially ... provide efficient thermal transfer to samples within ... the HT96 Isothermal Block replaces Cat. No. ... allowing for compatibility with robotic applications. The ...
Biology Products: